United States Patent 10,240,205: Natalizumab + JCV-PML Risk Stratification Using Absence of Specific Host Genetic Variants
United States Patent 10,240,205 claims methods for treating a subject with natalizumab while lowering the subject’s risk of progressive multifocal leukoencephalopathy (PML) linked to John Cunningham virus (JCV). The claimed risk reduction is conditioned on the subject being negative for one or more specific genetic variations (by genetic assay), with variants mapped to UCSC hg19 coordinates and located in or affecting a defined set of human immune-related genes, including CHD7, IFIH1, IGLL1, MAVS, PLCG2, SHARPIN, TCIRG1 and others. Claims further impose statistical thresholds (odds ratio) and specify assay modalities and clinical test context (e.g., JCV antibody, CD62L, CSF IgM oligoclonal bands).
The landscape implication for investors and R&D leaders: the patent is not a natalizumab composition claim. It is a patient-selection / diagnostics-linked treatment claim that attempts to convert host genotype negative status into actionable prescribing guidance to mitigate PML risk.
What does US 10,240,205 actually claim (core scope and limiting features)?
Claim 1 is the key independent claim
Claim 1 defines a method:
- Treat a condition in a subject needing natalizumab therapy
- With a therapeutically effective amount of natalizumab
- Where the subject has a decreased risk of PML due to brain infection by JCV
- Decreased risk is associated with:
- absence of one or more genetic variations in the subject
- subject tested by a genetic assay
- subject identified as not having the genetic variations
- Each genetic variation is said to disrupt or modulate one of a defined gene set:
- CHD7, IFIH1, IGLL1, MAVS, PLCG2, SHARPIN, TCIRG1
- plus “any combinations thereof”
- Variant list is defined with chromosome coordinates (UCSC hg19) and base changes, including combinations such as:
- chr8:61654298 T>A
- chr2:163136505 C>G
- chr22:23917192 G>T
- chr20:3846397 C>T
- chr16:81942175 A>G
- chr8:145154222 G>A
- chr11:67818269 G>A
- chr8:145154824 A>C
- chr22:23915745 G>A
- chr20:3843027 C>A
- “any combinations thereof”
- Explicitly anchored to coordinate system:
- “chromosome positions ... defined with respect to UCSC hg19”
Critical narrowing feature: the risk decrease is tied to absence of specific variants, not presence.
Claim 2 narrows the indication
- Condition = multiple sclerosis or a relapsing form of multiple sclerosis.
Claim 25 adds Crohn’s disease
- Condition = Crohn's disease.
Claims 3, 18 add statistical OR thresholds
Claim 3:
- OR of the genetic variation(s) is 3 or more, with the OR formula expressed as:
- [D_D/D_N]/[N_D/N_N]
- Diseased cohort has PML, non-diseased cohort does not
Claim 18:
Key interpretive risk for infringement analysis: the method claim is drafted so that genetic negativity is the operational trigger, but OR thresholds (3+ or 6+) are embedded as limitations in dependent claims, potentially allowing design-around by arguing OR < threshold, or that the specific variant set used is not the one validated at those OR levels.
Claims 4, 5, 13 define testing workflow
Claim 4:
- Includes testing the subject for presence of the variations prior to administering natalizumab.
Claim 5:
- Genetic assay has diagnostic yield of at least 20%.
Claim 13:
- Assay modalities include:
- microarray, PCR, sequencing, nucleic acid hybridization, or combinations.
Claims 14–15 connect with JCV antibody context
Claim 14:
- subject has been tested with a JCV-antibody test.
Claim 15:
- JCV-antibody test does not detect JCV.
This aligns with the known clinical risk management axis for natalizumab PML: JCV antibody positivity is often treated as a major risk marker; the patent conditions add genotype absence on top of that.
Claims 19 adds alternative clinical test predicates
- subject has been tested with CD62L or CSF IgM oligoclonal bands tests.
Claims 6–12, 21–24 specify single-variant embodiments
Dependent claims isolate individual variants from the list, including (non-exhaustive):
- chr16:81942175 A>G (Claim 6)
- chr8:145154222 G>A (Claim 7)
- chr2:163136505 C>G (Claim 9)
- chr8:61654298 T>A (Claim 10)
- chr22:23917192 G>T (Claim 11)
- chr20:3846397 C>T (Claim 12)
- chr11:67818269 G>A (Claim 21)
- chr8:145154824 A>C (Claim 22)
- chr22:23915745 G>A (Claim 23)
- chr20:3843027 C>A (Claim 24)
Practical effect: the patent creates multiple hooks to capture different test panels or different genotype reports that include any of these loci.
Claims 8, 16, 20 tie multi-variant structure and “other variants” filtering
Claim 8:
- first genetic variation disrupts/modulates one specified gene
- second genetic variation disrupts/modulates corresponding gene “according to Tables 3 and 6.”
Claims 16 and 20:
- subject identified as not having one or more other genetic variations according to Tables 19–24 (Claim 16) or Tables 3 and 6 (Claim 20)
Critical detail: the claim language uses reference-to-tables for the “other genetic variations” universe. That can increase enforceability against exact-panel users but also increases invalidity and construction risk if table incorporation is unclear.
Claims 26–27 describe sample qualification controls
These dependent claims focus on establishing non-duplicate samples and consistency checks:
- Claim 26: confirm each biological sample is not a duplicate based on nucleic acid information
- Claim 27: determine sex genotype from nucleic acid and confirm sex genotype matches sex phenotype of the donor
How strong is the patent’s technical logic versus existing PML risk management?
The patent’s novelty attempt
The claimed approach links natalizumab prescribing to host genomic risk stratification for JCV-associated PML. Clinically, PML risk management already uses:
- JCV antibody status
- treatment duration
- prior immunosuppressant use
- other emerging biomarkers
US 10,240,205 adds a second axis:
- absence of specific genetic variations associated with PML risk (OR-based cohorts)
Strengths in claim architecture
- Operational clarity: “administer natalizumab” only when the subject is negative for defined variants detected by a genetic assay.
- Defined loci: multiple explicit coordinate-level variants are enumerated, reducing ambiguity in what constitutes “the one or more genetic variations.”
- Multiple assay formats: broad assay embodiments (microarray/PCR/sequencing/hybridization) reduce the chance that an accused infringer can avoid by changing lab method.
- Multi-gene immune pathway framing: CHD7, IFIH1, MAVS, PLCG2, SHARPIN, and TCIRG1 collectively map to innate immune sensing, antiviral signaling, and immune regulation, which supports biological plausibility for a PML host susceptibility model.
Weaknesses / friction points
- Absence-based protection can be harder to enforce in practice because many commercial genetic tests report “presence/absence” but the clinical decision is often not phrased as “decreased PML risk due to absence of specific variants.” Enforcement would turn on claim construction: does the provider’s process and the lab report satisfy the “decreased risk is associated with an absence” limitation?
- Coordinate anchoring to hg19: if clinical testing uses different reference genomes (e.g., GRCh38) without strict mapping to hg19-equivalent positions, litigation may hinge on whether “chromosome positions ... defined with respect to UCSC hg19” is met by equivalent remapping.
- Table-dependent “other variants”: dependent claims referencing “Tables 3 and 6” and “Tables 19-24” can create claim-construction complexity. The broader the “other variants” set, the more the validity battle can leverage whether those variants were actually taught, supported, or enabled in the specification.
- OR thresholds only in dependent claims: if a clinical workflow aims for “absence” testing without demonstrating that OR thresholds of specific embodiments are satisfied in the relevant dataset, it may evade dependent-claim limitations.
What is the practical infringement trigger? (workflow mapping to dependent claims)
Core trigger (Claim 1)
A party practices Claim 1 by:
- Identifying a subject who needs natalizumab for MS or another covered condition (Claim 2 or Claim 25)
- Performing a genetic assay for the listed variants
- Documenting that the subject is not having one or more of the variants
- Administering natalizumab
- Doing so in the context that the subject has a “decreased risk of PML” due to JCV brain infection, with decreased risk associated with the variant absence
Additional triggers in dependent claims
- Timing: genetic testing occurs prior to natalizumab administration (Claim 4)
- Assay performance: yield ≥ 20% (Claim 5)
- Assay type: microarray/PCR/seq/hybridization (Claim 13)
- JCV context: JCV antibody tested negative (Claim 14–15) or other tests (Claim 19)
- OR validation: the selected variant set has OR ≥ 3 or OR ≥ 6 (Claims 3 and 18)
- Panel expansion: negativity for “other genetic variations” defined by specific tables (Claims 16 and 20)
- Sample governance: non-duplicate confirmation and sex-genotype confirmation (Claims 26–27)
Claim-by-claim criticality: what is most litigable?
| Claim element |
What it locks down |
Why it matters in enforcement or validity |
| “absence” of one or more genetic variations |
Liability attaches to the negative genotype status |
Many clinical workflows do not condition treatment on the absence of enumerated loci; courts may look at whether “associated with” is a factual scientific correlation or a mere intended use |
| Explicit hg19 loci list |
Defines subject matter with coordinate specificity |
Enables mapping to test reports; also enables design-around via different variant panels or reference genome mapping issues |
| Gene disruption/modulation statement |
Ties loci to gene function |
Can be attacked if functional linkage is unsupported or overbroad |
| OR thresholds (3+, 6+) |
Adds quantitative proof requirement (dependent claims) |
If dependent claims are asserted, challengers can attack cohort design or replicability |
| Genetic assay yield ≥20% |
Adds performance metric |
Can become an experimental evidence battleground |
| JCV antibody negative and CD62L/CSF IgM |
Adds medical test predicate |
Allows argument that the patent is not broadly applicable to all natalizumab users, potentially narrowing infringement but also strengthening clinical justification |
| Table-referenced “other genetic variations” |
Expands or constrains the variant set |
Table incorporation increases construction disputes |
Patent landscape: likely competitive positions and design-around paths
Because the independent claim is tightly tethered to:
- natalizumab
- PML risk
- JCV-related context
- specific host genetic variants (hg19 coordinates)
- genetic assay-negative status
the competitive space breaks into four buckets:
-
Genotype-negative natalizumab use with the same loci
- Highest infringement risk if implemented as written.
-
Genotype-negative natalizumab use using alternative loci
- Potential design-around if the alternative loci are not within the enumerated list and are not part of “other genetic variations” in the incorporated tables.
-
Broader risk scores that do not require absence of the enumerated variants
- Lower infringement risk if the workflow never requires being “identified as not having” these specific genetic variations.
-
Testing and treatment decisions based solely on JCV antibody and standard clinical factors
- Likely outside scope of Claim 1’s “genetic assay” and “absence of the one or more genetic variations” limitations.
Commercial implication: if market participants adopt a multigenic PML risk panel, the patent’s enforceability will likely depend on whether their algorithm requires negativity for the specific coordinates listed here, versus using different biomarkers or odds ratios derived from different studies.
Key Takeaways
- US 10,240,205 is a diagnostic-linked treatment patent: it claims natalizumab administration conditioned on absence of specific hg19 host genetic variants tied to immune genes implicated in antiviral sensing and immune regulation.
- Enforcement hinges on workflow facts: whether the provider’s process uses a genetic assay to identify the subject as negative for the enumerated variants before giving natalizumab, and whether the claimed “decreased PML risk” is supported as an operative correlation.
- The claim set is modular: dependent claims add constraints (OR thresholds, yield ≥20%, JCV antibody negative, CD62L/CSF markers, negativity for “other variants,” and sample handling governance).
- Design-around opportunities likely exist via shifting to different loci, not using the required negative status for these specific coordinates, or using risk strategies not anchored to the enumerated variants.
FAQs
1) Is US 10,240,205 a natalizumab formulation patent?
No. It claims a method of treating using natalizumab tied to genetic assay results for host susceptibility to JCV-associated PML.
2) What is the operational criterion in Claim 1?
The subject must be identified as not having one or more enumerated genetic variations via a genetic assay before natalizumab administration.
3) Does the patent require JCV antibody testing?
Claim 1 does not. Claims 14–15 add JCV-antibody context, including the case where the test does not detect JCV.
4) What role do odds ratios play?
OR thresholds (≥3 in Claim 3; ≥6 in Claim 18) appear in dependent claims and can become central to validity and infringement disputes depending on which dependent claims are asserted.
5) Why does hg19 matter?
The patent defines chromosome positions with respect to UCSC hg19. That can affect how genetic test reports and coordinate mappings are argued for or against claim coverage.
References
[1] United States Patent 10,240,205. Claims as provided in user prompt.
